vs
Astrana Health, Inc.（ASTH）与STEPAN CO（SCL）财务数据对比。点击上方公司名可切换其他公司
Astrana Health, Inc.的季度营收约是STEPAN CO的1.6倍（$950.5M vs $604.5M），STEPAN CO净利率更高（3.3% vs 0.7%，领先2.6%），Astrana Health, Inc.同比增速更快（42.9% vs 1.9%），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 4.2%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
斯特潘公司是一家美国特种化学品制造商，总部位于伊利诺伊州诺斯布鲁克，1932年由小阿尔弗雷德·C·斯特潘创立，现有约2000名员工，目前由创始人的孙子小F·奎因·斯特潘执掌。该公司是全球最大的阴离子表面活性剂商品生产商，产品用于提升洗涤剂、洗发水、牙膏及化妆品的起泡与清洁能力。
ASTH vs SCL — 直观对比
营收规模更大
ASTH
是对方的1.6倍
$604.5M
营收增速更快
ASTH
高出41.0%
1.9%
净利率更高
SCL
高出2.6%
0.7%
两年增速更快
ASTH
近两年复合增速
4.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $604.5M |
| 净利润 | $6.6M | $19.7M |
| 毛利率 | — | 10.7% |
| 营业利润率 | 1.9% | 4.7% |
| 净利率 | 0.7% | 3.3% |
| 营收同比 | 42.9% | 1.9% |
| 净利润同比 | 184.4% | — |
| 每股收益（稀释后） | $0.12 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHSCL
| Q1 26 | — | $604.5M | ||
| Q4 25 | $950.5M | $553.9M | ||
| Q3 25 | $956.0M | $590.3M | ||
| Q2 25 | $654.8M | $594.7M | ||
| Q1 25 | $620.4M | $593.3M | ||
| Q4 24 | $665.2M | $525.6M | ||
| Q3 24 | $478.7M | $546.8M | ||
| Q2 24 | $486.3M | $556.4M |
净利润ASTHSCL
| Q1 26 | — | $19.7M | ||
| Q4 25 | $6.6M | $5.0M | ||
| Q3 25 | $373.0K | $10.8M | ||
| Q2 25 | $9.4M | $11.3M | ||
| Q1 25 | $6.7M | $19.7M | ||
| Q4 24 | $-7.8M | $3.4M | ||
| Q3 24 | $16.1M | $23.6M | ||
| Q2 24 | $19.2M | $9.5M |
毛利率ASTHSCL
| Q1 26 | — | 10.7% | ||
| Q4 25 | — | 9.3% | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | — | 12.1% | ||
| Q1 25 | — | 12.7% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 12.5% |
营业利润率ASTHSCL
| Q1 26 | — | 4.7% | ||
| Q4 25 | 1.9% | 1.9% | ||
| Q3 25 | 2.0% | 3.7% | ||
| Q2 25 | 3.1% | 3.0% | ||
| Q1 25 | 3.3% | 4.8% | ||
| Q4 24 | 0.1% | 1.5% | ||
| Q3 24 | 5.9% | 4.4% | ||
| Q2 24 | 6.2% | 3.4% |
净利率ASTHSCL
| Q1 26 | — | 3.3% | ||
| Q4 25 | 0.7% | 0.9% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 1.4% | 1.9% | ||
| Q1 25 | 1.1% | 3.3% | ||
| Q4 24 | -1.2% | 0.6% | ||
| Q3 24 | 3.4% | 4.3% | ||
| Q2 24 | 3.9% | 1.7% |
每股收益（稀释后）ASTHSCL
| Q1 26 | — | $0.86 | ||
| Q4 25 | $0.12 | $0.22 | ||
| Q3 25 | $0.01 | $0.47 | ||
| Q2 25 | $0.19 | $0.50 | ||
| Q1 25 | $0.14 | $0.86 | ||
| Q4 24 | $-0.14 | $0.14 | ||
| Q3 24 | $0.33 | $1.03 | ||
| Q2 24 | $0.40 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | — |
| 总债务越低越好 | — | $328.4M |
| 股东权益账面价值 | $779.3M | $1.2B |
| 总资产 | $2.2B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资ASTHSCL
| Q1 26 | — | — | ||
| Q4 25 | $429.5M | $132.7M | ||
| Q3 25 | $463.4M | $118.5M | ||
| Q2 25 | $342.1M | $88.9M | ||
| Q1 25 | $260.9M | $107.5M | ||
| Q4 24 | $290.8M | $99.7M | ||
| Q3 24 | $350.3M | $147.3M | ||
| Q2 24 | $327.7M | $124.7M |
总债务ASTHSCL
| Q1 26 | — | $328.4M | ||
| Q4 25 | — | $626.7M | ||
| Q3 25 | — | $655.5M | ||
| Q2 25 | — | $658.0M | ||
| Q1 25 | — | $659.3M | ||
| Q4 24 | — | $625.4M | ||
| Q3 24 | — | $688.5M | ||
| Q2 24 | — | $657.1M |
股东权益ASTHSCL
| Q1 26 | — | $1.2B | ||
| Q4 25 | $779.3M | $1.2B | ||
| Q3 25 | $775.5M | $1.2B | ||
| Q2 25 | $765.5M | $1.2B | ||
| Q1 25 | $745.4M | $1.2B | ||
| Q4 24 | $712.7M | $1.2B | ||
| Q3 24 | $704.6M | $1.2B | ||
| Q2 24 | $678.9M | $1.2B |
总资产ASTHSCL
| Q1 26 | — | $2.3B | ||
| Q4 25 | $2.2B | $2.4B | ||
| Q3 25 | $2.2B | $2.4B | ||
| Q2 25 | $1.4B | $2.4B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.3B | $2.3B |
负债/权益比ASTHSCL
| Q1 26 | — | 0.28× | ||
| Q4 25 | — | 0.50× | ||
| Q3 25 | — | 0.53× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.56× | ||
| Q2 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | — |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | — |
| 自由现金流率自由现金流/营收 | -0.6% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | -0.44× | — |
| 过去12个月自由现金流最近4个季度 | $104.5M | — |
8季度趋势，按日历期对齐
经营现金流ASTHSCL
| Q1 26 | — | — | ||
| Q4 25 | $-2.9M | $60.0M | ||
| Q3 25 | $10.0M | $69.8M | ||
| Q2 25 | $90.9M | $11.2M | ||
| Q1 25 | $16.6M | $6.9M | ||
| Q4 24 | $-10.9M | $68.3M | ||
| Q3 24 | $34.0M | $22.7M | ||
| Q2 24 | $23.2M | $29.5M |
自由现金流ASTHSCL
| Q1 26 | — | — | ||
| Q4 25 | $-6.0M | $25.4M | ||
| Q3 25 | $7.4M | $40.2M | ||
| Q2 25 | $89.5M | $-14.4M | ||
| Q1 25 | $13.6M | $-25.8M | ||
| Q4 24 | $-13.5M | $32.1M | ||
| Q3 24 | $31.7M | $-4.0M | ||
| Q2 24 | $20.4M | $-208.0K |
自由现金流率ASTHSCL
| Q1 26 | — | — | ||
| Q4 25 | -0.6% | 4.6% | ||
| Q3 25 | 0.8% | 6.8% | ||
| Q2 25 | 13.7% | -2.4% | ||
| Q1 25 | 2.2% | -4.3% | ||
| Q4 24 | -2.0% | 6.1% | ||
| Q3 24 | 6.6% | -0.7% | ||
| Q2 24 | 4.2% | -0.0% |
资本支出强度ASTHSCL
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 6.3% | ||
| Q3 25 | 0.3% | 5.0% | ||
| Q2 25 | 0.2% | 4.3% | ||
| Q1 25 | 0.5% | 5.5% | ||
| Q4 24 | 0.4% | 6.9% | ||
| Q3 24 | 0.5% | 4.9% | ||
| Q2 24 | 0.6% | 5.3% |
现金转化率ASTHSCL
| Q1 26 | — | — | ||
| Q4 25 | -0.44× | 11.99× | ||
| Q3 25 | 26.69× | 6.44× | ||
| Q2 25 | 9.65× | 0.99× | ||
| Q1 25 | 2.48× | 0.35× | ||
| Q4 24 | — | 20.38× | ||
| Q3 24 | 2.11× | 0.96× | ||
| Q2 24 | 1.21× | 3.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
SCL
| Surfactants | $453.7M | 75% |
| Polymers | $130.0M | 22% |
| Specialty Products | $20.8M | 3% |
